Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

113 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Predictive and prognostic significance of CD8+ tumor-infiltrating lymphocytes in patients with luminal B/HER 2 negative breast cancer treated with neoadjuvant chemotherapy.
Al-Saleh K, Abd El-Aziz N, Ali A, Abozeed W, Abd El-Warith A, Ibraheem A, Ansari J, Al-Rikabi A, Husain S, Nabholtz JM. Al-Saleh K, et al. Among authors: nabholtz jm. Oncol Lett. 2017 Jul;14(1):337-344. doi: 10.3892/ol.2017.6144. Epub 2017 May 10. Oncol Lett. 2017. PMID: 28693173 Free PMC article.
Triple Negative Breast Cancer: A Tale of Two Decades.
Ali AM, Ansari JAK, El-Aziz NMA, Abozeed WN, Warith AMA, Alsaleh K, Nabholtz JM. Ali AM, et al. Among authors: nabholtz jm. Anticancer Agents Med Chem. 2017;17(4):491-499. doi: 10.2174/1871520616666160725112335. Anticancer Agents Med Chem. 2017. PMID: 27456662 Review.
Response to Induction Neoadjuvant Hormonal Therapy Using Upfront 21-Gene Breast Recurrence Score Assay-Results From the SAFIA Phase III Trial.
AlSaleh K, Al Zahwahry H, Bounedjar A, Oukkal M, Saadeddine A, Mahfouf H, Bouzid K, Bensalem A, Filali T, Abdel-Razeq H, Larbaoui B, Kandil A, Abulkhair O, Al Foheidi M, Errihani H, Ghosn M, Abdel-Aziz N, Arafah M, Boussen H, Dabouz F, Rasool H, Bahadoor M, Ayari J, Kullab S, Nabholtz JM. AlSaleh K, et al. Among authors: nabholtz jm. JCO Glob Oncol. 2021 Jun;7:811-819. doi: 10.1200/GO.20.00575. JCO Glob Oncol. 2021. PMID: 34086481 Free PMC article. Clinical Trial.
Breast-cancer detection using blood-based infrared molecular fingerprints.
Kepesidis KV, Bozic-Iven M, Huber M, Abdel-Aziz N, Kullab S, Abdelwarith A, Al Diab A, Al Ghamdi M, Hilal MA, Bahadoor MRK, Sharma A, Dabouz F, Arafah M, Azzeer AM, Krausz F, Alsaleh K, Zigman M, Nabholtz JM. Kepesidis KV, et al. Among authors: nabholtz jm. BMC Cancer. 2021 Dec 2;21(1):1287. doi: 10.1186/s12885-021-09017-7. BMC Cancer. 2021. PMID: 34856945 Free PMC article.
Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies.
Radosevic-Robin N, Selenica P, Zhu Y, Won HH, Berger MF, Ferrando L, Cocco E, Privat M, Ponelle-Chachuat F, Abrial C, Nabholtz JM, Penault-Llorca F, Reis-Filho JS, Scaltriti M. Radosevic-Robin N, et al. Among authors: nabholtz jm. NPJ Breast Cancer. 2021 Sep 17;7(1):124. doi: 10.1038/s41523-021-00334-5. NPJ Breast Cancer. 2021. PMID: 34535679 Free PMC article.
Open-label randomised phase III trial of vinflunine versus an alkylating agent in patients with heavily pretreated metastatic breast cancer.
Cortes J, Perez-Garcia J, Levy C, Gómez Pardo P, Bourgeois H, Spazzapan S, Martínez-Jañez N, Chao TC, Espié M, Nabholtz JM, Gonzàlez Farré X, Beliakouski V, Román García J, Holgado E, Campone M. Cortes J, et al. Among authors: nabholtz jm. Ann Oncol. 2018 Apr 1;29(4):881-887. doi: 10.1093/annonc/mdy051. Ann Oncol. 2018. PMID: 29481630 Free article. Clinical Trial.
Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact.
Nabholtz JM, Abrial C, Mouret-Reynier MA, Dauplat MM, Weber B, Gligorov J, Forest AM, Tredan O, Vanlemmens L, Petit T, Guiu S, Van Praagh I, Jouannaud C, Dubray-Longeras P, Tubiana-Mathieu N, Benmammar KE, Kullab S, Bahadoor MR, Radosevic-Robin N, Kwiatkowski F, Desrichard A, Cayre A, Uhrhammer N, Chalabi N, Chollet P, Penault-Llorca F. Nabholtz JM, et al. Ann Oncol. 2014 Aug;25(8):1570-7. doi: 10.1093/annonc/mdu183. Epub 2014 May 14. Ann Oncol. 2014. PMID: 24827135 Free article. Clinical Trial.
Mastectomy with immediate breast reconstruction after neoadjuvant chemotherapy and radiation therapy. A new option for patients with operable invasive breast cancer. Results of a 20 years single institution study.
Monrigal E, Dauplat J, Gimbergues P, Le Bouedec G, Peyronie M, Achard JL, Chollet P, Mouret-Reynier MA, Nabholtz JM, Pomel C. Monrigal E, et al. Among authors: nabholtz jm. Eur J Surg Oncol. 2011 Oct;37(10):864-70. doi: 10.1016/j.ejso.2011.07.009. Epub 2011 Aug 16. Eur J Surg Oncol. 2011. PMID: 21843920
Can pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer?
Wang-Lopez Q, Chalabi N, Abrial C, Radosevic-Robin N, Durando X, Mouret-Reynier MA, Benmammar KE, Kullab S, Bahadoor M, Chollet P, Penault-Llorca F, Nabholtz JM. Wang-Lopez Q, et al. Among authors: nabholtz jm. Crit Rev Oncol Hematol. 2015 Jul;95(1):88-104. doi: 10.1016/j.critrevonc.2015.02.011. Epub 2015 Mar 4. Crit Rev Oncol Hematol. 2015. PMID: 25900915 Review.
113 results